Pluri Inc(PLUR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.87 | Insider Own | 48.98% | Shs Outstand | 10.4M | Perf Week | -11.97% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.3M | Perf Month | -28.57% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 11.06% | Short Float | 0.25% | Perf Quarter | -44.69% |
| Income | -0.03B | P/S | 14.29 | EPS this Y | - | Inst Trans | -0.04% | Short Ratio | 0.52 | Perf Half Y | -62.57% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -80.48% | Short Interest | 0.02M | Perf YTD | -58.19% |
| Book/sh | -1.78 | P/C | 1.62 | EPS past 3/5Y | 29.68% 22.58% | ROE | - | 52W High | -75.84% ($5.17) | Perf Year | -73.61% |
| Cash/sh | 0.77 | P/FCF | - | Sales past 3/5Y | 78.73% 125.33% | ROIC | - | 52W Low | 0% ($1.25) | Perf 3Y | -73.97% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 20.37% | Gross Margin | -3.15% | Volatility(W/M) | 11.68% 8.86% | Perf 5Y | -94.76% |
| Dividend TTM | - | EV/Sales | 41.77 | Sales Y/Y TTM | 4.35% | Oper. Margin | -2410.84% | ATR (14) | 0.14 | Perf 10Y | -99.06% |
| Dividend Ex-Date | - | Quick Ratio | 0.33 | EPS Q/Q | 41.08% | Profit Margin | -2366.91% | RSI (14) | 33.29 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.33 | Sales Q/Q | -60.89% | SMA20 | -17.93% ($1.52) | Beta | 0.65 | Target Price | $12 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -25.55% ($1.68) | Rel Volume | 0.86 | Prev Close | $1.37 |
| Employees | 127 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -55.06% ($2.78) | Avg Volume(3M) | 0.03M | Price | $1.25 |
| IPO | 2003/4/16 | Option/Short | No/Yes | Trades | 240 | Volume | 25,377 | Change | -8.76% |
Company
PLUR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Pluristem () is a biotech company headquartered in Haifa, Israel. Built around its proprietary 3D cell mass-production platform, it operates across regenerative medicine, cell agriculture, food tech, and CDMO (contract development and manufacturing) services. The company is developing its PLX series of cell therapy candidates targeting conditions such as peripheral artery disease and hematopoietic recovery, while also extending its platform into the food sector with cultivated meat and cell-based coffee.
Over the past 1 year, on the lower side
76% below its 1-year high.
PLUR has weak earning power
-2410.84% of revenue is kept as operating profit.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -74.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 11.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
DFIS 0.00%It ranks #4 in the industry
Based on market cap of $15M.
PLUR $15M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is PLUR?
PLUR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PLUR?
The market cap of PLUR is approximately $15M, ranking 5,384 within its sector.
What is the 52-week high and low for PLUR?
PLUR has recorded a 52-week high of $5.17 and a low of $1.25.
